Apexigen Inc (APGN)

[cash4]

Apexigen Inc. (APGN)
Roth Capital: Buy, $15 Target

https://pennystocks.com/featured/2023/01/25/4-penny-stocks-to-buy-according-to-analysts-targets-over-600/

Finally, Apexigen has pulled an about-face since the start of the new year. The company hit fresh, 52-week lows on the first day of trading for 2023 but so far has bounced back more than 100%. If analysts are to be believed, they expect much more, which we’ll discuss later in this section.

Apexigen develops antibody-based therapeutics for cancer treatment and recently posted new Phase 2 data. This data evaluated its sotigalimab in treating tumors in patients with esophageal/gastro-esophageal junction (E/GEJ) cancer and a separate study in rectal cancer tumors. The data was recently presented at the ASCO Gastrointestinal Cancers Symposium earlier this month.


Recent news regarding a $2.8 million financing deal doesn’t seem to have impacted the market. The funding round is expected to close by the end of this month, with proceeds going toward the ongoing Phase 2 study of sotigalimab.

What is the APGN stock forecast? Roth Capital recently reinstated its coverage of the company. The firm gave a Buy rating and price target of $15. APGN stock closed at $1.99 on Tuesday, which puts Roth Capitals forecast 654% higher.